Strides Arcolab completes $1.6 billion sale of subsidiary to Mylan
Clients Strides Arcolab Limited
Jones Day advised India-based pharmaceutical company Strides Arcolab Limited ("Strides") on the antitrust aspects of the sale to Mylan Inc. of its Agila Specialties Global Pte. Ltd. ("Agila") subsidiary for $1.6 billion in cash. The deal was announced in a company press release on February 28, 2013.
Headquartered in Bangalore, India, Agila is a developer, manufacturer, and marketer of high-quality generic injectable products. Agila had the highest number of FDA approved generic injectables from 2008 to 2010. The deal is expected to expand Mylan’s global footprint and increase its injectable portfolio to approximately 700 drugs.